Jadenu Indications/Uses

JADENU (deferasirox) is indicated in the management of chronic iron overload in patients with transfusion-dependent anemias aged 6 years or older.
JADENU is also indicated in the management of chronic iron overload in patients with transfusion-dependent anemias aged two to five who cannot be adequately treated with deferoxamine.
JADENU is also indicated for the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older.
Therapy with JADENU should be initiated and maintained by physicians experienced in the treatment of chronic iron overload due to blood transfusions.
Pediatrics (2 to 16 years of age): There are limited data available on the use of deferasirox in children aged 2 to 5 (see Use in children under Precautions). The overall exposure of deferasirox in young children (aged 2 to 5) was about 50% lower than in adults and this age group may require higher maintenance doses than are necessary in adults (see Dosage & Administration).
Geriatrics (≥ 65 years of age): Four hundred and thirty-one (431) patients ≥ 65 years of age have been studied in clinical trials of deferasirox (see Use in elderly under Precautions). The pharmacokinetics of deferasirox have not been studied in elderly patients. In clinical trials of deferasirox, elderly patients experienced a higher frequency of adverse reactions than younger patients and should be monitored closely for adverse reactions that may require a dose adjustment.